درباره این اپیزود
In this episode of Whimsical Wavelengths, Dr. Jeffrey Zurek sits down with Dr. Katherine Borden, a professor at Northwestern University's Feinberg School of Medicine, to explore the ancient and vital protein eIF4E (or 4E). Long misunderstood as a simple rate-limiting factor in protein synthesis, 4E acts as a master regulator of RNA processing, transport, and translation. Dr. Borden shares the serendipitous discovery of finding 4E in the cell nucleus, how cancer cells hijack this machinery to drive aggressive disease states like acute myeloid leukemia (AML), and the ongoing journey of translating basic science into clinical trials using repurposed antivirals.
Sub-Themes and Highlights
The Research Process and Serendipity: How a control experiment looking for viral interactions led to a major paradigm shift in understanding 4E’s nuclear localization.
Social Impacts and Translational Health: Exploring the challenges of drug resistance, glucuronidation, and the human side of clinical trials for heavily pretreated patients.
Community and Collaboration: Highlighting the Canadian Sciences Speakers Network (CSSN) as a vital tool for connecting researchers, media, and the public beyond traditional word-of-mouth networks.
Chapters
- 00:00 Introducing eIF4E
- 02:12 Discovering the CSSN network.
- 03:45 Meeting Dr. Katherine Borden.
- 07:55 Cellular stress and paper cuts.
- 10:48 Evolution of 4E research.
- 17:05 The nuclear eureka moment.
- 19:18 The Goldilocks protein zone.
- 21:45 Ribavirin clinical trials.
- 26:15 The biology of drug resistance.
- 33:10 The tumor microenvironment.
- 36:30 Future outlook on therapy.
- 38:50 Patient thanks and atom jokes.
Links:
Support: Pateron
Socials: Bluesky | Instagram | Facebook
Whimsical Wavelengths: Deep-dive conversations where a working scientist unpacks how we know what we know, one paper, one idea, or whimsical detour at a time. Hosted by Dr. Jeffrey Zurek (P.Geo).
یادداشت ها را نشان دهید 🔗
رونوشت 🔗
00:00:11.319 --> 00:00:16.879
lost in the fog of a cosmic storm floating on
00:00:16.879 --> 00:00:21.120
whimsical wavelengths is the norm dancing through
00:00:21.120 --> 00:00:27.379
the stars chasing spectrums of light riding the
00:00:27.379 --> 00:00:31.649
waves that are just out It's season three, and
00:00:31.649 --> 00:00:34.130
I'm your host, Dr. Jeffrey Zurich, a volcanologist
00:00:34.130 --> 00:00:36.890
and geophysicist. Today, we're digging into cellular
00:00:36.890 --> 00:00:45.929
function, a protein called EIF4E, or just 4E.
00:00:46.710 --> 00:00:50.189
Either way, it doesn't exactly roll off the tongue.
00:00:50.390 --> 00:00:52.829
It doesn't have a name that would suggest importance,
00:00:53.189 --> 00:00:59.869
like dioxic ribonolic acid, or When you come
00:00:59.869 --> 00:01:03.289
across something really important, you expect...
00:01:03.289 --> 00:01:07.250
My name is Maximus Decimus Meridius. Sometimes
00:01:07.250 --> 00:01:10.409
it sounds like the vine of my first name. My
00:01:10.409 --> 00:01:16.150
name is Jeff. But it is important. 4E, as I'm
00:01:16.150 --> 00:01:18.489
going to be calling it, as I learn in the interview,
00:01:18.650 --> 00:01:22.109
wait for it, is the way they refer to it, is
00:01:22.109 --> 00:01:24.950
the rate -limiting gatekeeper for building proteins
00:01:24.950 --> 00:01:27.519
in a cell. It escorts genetic blueprints through
00:01:27.519 --> 00:01:30.540
the editing and transport so the cell's factory
00:01:30.540 --> 00:01:34.700
can manufacture them. When a cell needs to divide,
00:01:35.040 --> 00:01:38.560
blood vessel growth, repair mechanisms, basically
00:01:38.560 --> 00:01:42.140
if a cell needs to create a new biological scaffolding,
00:01:42.159 --> 00:01:47.700
proteins, and therefore, 4E is involved. And
00:01:47.700 --> 00:01:51.359
it's not... Just humans. This protein is so ancient
00:01:51.359 --> 00:01:55.200
and foundational that complex life cannot live
00:01:55.200 --> 00:01:58.760
without it. Today we will explore this protein
00:01:58.760 --> 00:02:02.400
and what effect it has. What happens when there
00:02:02.400 --> 00:02:05.819
is too little and too much. Hint. We're going
00:02:05.819 --> 00:02:08.439
to be talking about cancer. Before getting into
00:02:08.439 --> 00:02:12.800
the actual episode, science sausage making time.
00:02:13.800 --> 00:02:16.219
I need to call out a relatively new Canadian
00:02:16.219 --> 00:02:20.620
organization for science communication. It is
00:02:20.620 --> 00:02:24.900
also a direct way for me to find Canadian researchers
00:02:24.900 --> 00:02:28.919
and guests. The organization is the Canadian
00:02:28.919 --> 00:02:31.979
Sciences Speakers Network. It can be hard to
00:02:31.979 --> 00:02:35.580
fathom that science tasks like reviewing grants
00:02:35.580 --> 00:02:39.199
still works a bit like a word -of -mouth system.
00:02:40.330 --> 00:02:42.629
Being able to fill grant panels with qualified
00:02:42.629 --> 00:02:46.930
people is a requirement, but only those on kind
00:02:46.930 --> 00:02:49.469
of a personal list or roller decks gets called
00:02:49.469 --> 00:02:52.830
upon. It causes the system to not work at its
00:02:52.830 --> 00:02:55.330
full potential, causing delays and other unintended
00:02:55.330 --> 00:02:58.990
consequences. We can also look outside of specific
00:02:58.990 --> 00:03:01.509
disciplines. For instance, how science communication
00:03:01.509 --> 00:03:06.569
is conducted, like in the media. It is also who
00:03:06.569 --> 00:03:09.979
you know. If you're on a journalist contact list
00:03:09.979 --> 00:03:12.639
when something in your field comes up, there
00:03:12.639 --> 00:03:15.560
is only one person they will call. And if they
00:03:15.560 --> 00:03:18.419
know no one, they go through the word of mouth
00:03:18.419 --> 00:03:21.719
method to find someone. The Canadian Science
00:03:21.719 --> 00:03:24.919
Speakers Network aims to make that much easier.
00:03:25.860 --> 00:03:28.840
Myself and today's guest, Dr. Katherine Borden,
00:03:29.039 --> 00:03:32.400
are both members. You can see our profiles and
00:03:32.400 --> 00:03:35.400
all the wonderful, knowledgeable science communicators
00:03:35.400 --> 00:03:42.870
at C -S -S -N -R -C -P -S dot C -A. Be sure to
00:03:42.870 --> 00:03:45.729
look for that in the show notes. So today's guest
00:03:45.729 --> 00:03:49.590
is Dr. Catherine Borden, a professor in the Feinberg
00:03:49.590 --> 00:03:52.069
School of Medicine at Northwestern University.
00:03:52.449 --> 00:03:55.449
The Borden Lab is at the cutting edge of researching
00:03:55.449 --> 00:04:00.409
4E and how it hijacks genetic messages that are
00:04:00.409 --> 00:04:03.310
edited and shipped out to force cells into an
00:04:03.310 --> 00:04:08.860
aggressive invasive. cancer state. Dr. Katherine
00:04:08.860 --> 00:04:11.919
Borden, welcome to Whimsical Wavelengths. Nice
00:04:11.919 --> 00:04:14.120
to be here. I really appreciate the opportunity
00:04:14.120 --> 00:04:18.259
to be part of your great podcast. Aww. Well,
00:04:18.379 --> 00:04:21.000
as I was wrapping up Season 2, I came across
00:04:21.000 --> 00:04:24.040
you and the Canadian Science Speakers Network.
00:04:24.279 --> 00:04:26.699
First off, thank you, you and your team, for
00:04:26.699 --> 00:04:28.240
collecting some of the best science communicators
00:04:28.240 --> 00:04:31.420
in Canada into one spot. I gotta say, it's gonna
00:04:31.420 --> 00:04:34.560
make my job going forward much, much easier.
00:04:35.210 --> 00:04:37.529
second before we jump into the research, how
00:04:37.529 --> 00:04:41.089
about we just dwell on it for a second and what
00:04:41.089 --> 00:04:43.370
is it and what problem is it trying to solve?
00:04:44.459 --> 00:04:50.100
So we nickname it CSSN, just for listeners. And
00:04:50.100 --> 00:04:52.019
the problem that it's trying to solve is that
00:04:52.019 --> 00:04:54.939
Canada is a big country, and we have a lot of
00:04:54.939 --> 00:04:58.240
talent here, and it's widely distributed. And
00:04:58.240 --> 00:05:01.459
so in order to harness that talent more efficiently,
00:05:01.660 --> 00:05:04.779
we developed this website, which is searchable
00:05:04.779 --> 00:05:08.980
for any kind of scientific or academic fields
00:05:08.980 --> 00:05:11.339
that you might be interested in knowing more
00:05:11.339 --> 00:05:16.019
about. there so that the government, the public,
00:05:16.300 --> 00:05:20.339
the press, academic institutions, funding agencies,
00:05:20.480 --> 00:05:23.959
industry boards, all of those places will have
00:05:23.959 --> 00:05:27.220
a chance to be able to not just use word -of
00:05:27.220 --> 00:05:30.980
-mouth networks, but to actually have a high
00:05:30.980 --> 00:05:34.220
-end search engine in order to identify individuals
00:05:34.220 --> 00:05:38.939
that could benefit their organizations. That's
00:05:38.939 --> 00:05:42.279
really what we hope the site can be used for
00:05:42.279 --> 00:05:44.879
and is starting to be used for. And I also just
00:05:44.879 --> 00:05:46.560
want to throw in that the site is completely
00:05:46.560 --> 00:05:50.860
not for profit. It's run by academics for academics
00:05:50.860 --> 00:05:54.899
and for the greater good. So there is no other
00:05:54.899 --> 00:05:58.720
agenda other than allowing Canadians to be highlighted
00:05:58.720 --> 00:06:02.000
and found who are particularly talented in a
00:06:02.000 --> 00:06:05.220
certain area. I find something strange that you
00:06:05.220 --> 00:06:07.740
just said there. It's almost like us scientists
00:06:07.740 --> 00:06:11.279
are almost hardwired for that sometimes, especially,
00:06:11.360 --> 00:06:14.279
I guess, when you're dealing with cancer in the
00:06:14.279 --> 00:06:17.160
health field. When it's taken up by scientists
00:06:17.160 --> 00:06:19.220
who don't get paid for something, we almost feel
00:06:19.220 --> 00:06:21.759
like it's an inflective response that we have
00:06:21.759 --> 00:06:24.540
to mention it. I guess I just wanted to be sure
00:06:24.540 --> 00:06:28.360
that people didn't feel that there was some hidden
00:06:28.360 --> 00:06:33.430
agenda. And also, you know, as a scientist, I'd
00:06:33.430 --> 00:06:37.029
like to be able to be found as well. And as a
00:06:37.029 --> 00:06:40.149
researcher who's organized big meetings, I found
00:06:40.149 --> 00:06:42.829
that there was no Canadian resource that would
00:06:42.829 --> 00:06:46.269
help me organize a better meeting or to organize
00:06:46.269 --> 00:06:50.709
a better board. And so it's a real problem. And
00:06:50.709 --> 00:06:54.810
I think only those of us who are scientists or
00:06:54.810 --> 00:06:58.810
in allied fields of STEM in particular have to
00:06:58.810 --> 00:07:02.240
kind of... build this to help ourselves. And
00:07:02.240 --> 00:07:05.480
I think it's a crucial time for the public interest
00:07:05.480 --> 00:07:08.079
to really be able to reach out to understand
00:07:08.079 --> 00:07:12.199
from experts what the real science is behind
00:07:12.199 --> 00:07:15.759
the headlines. Yeah. And I think also I'm going
00:07:15.759 --> 00:07:17.740
to have a running theme as part of the season,
00:07:17.920 --> 00:07:19.920
perhaps, is turning science back into a human
00:07:19.920 --> 00:07:22.300
conversation. So it's just putting humans in
00:07:22.300 --> 00:07:24.060
front of the people who are looking for that
00:07:24.060 --> 00:07:27.420
information. I completely agree with that. So,
00:07:27.540 --> 00:07:29.160
we're going to get on to the episode, and like
00:07:29.160 --> 00:07:31.899
most episodes, this started with a peer -reviewed
00:07:31.899 --> 00:07:34.860
article. And I'm going to try to not butcher
00:07:34.860 --> 00:07:39.800
the pronunciation of things. The eukaryotic translation
00:07:39.800 --> 00:07:46.220
initiation factor ELF4E unexpectedly acts in
00:07:46.220 --> 00:07:49.560
splicing, thereby coupling RNA processing with
00:07:49.560 --> 00:07:54.279
translation in bio -SEs. To get from here to
00:07:54.279 --> 00:07:56.560
understanding the results, let's start with how,
00:07:56.579 --> 00:07:59.199
I guess, a healthy cell functions. Like, how
00:07:59.199 --> 00:08:01.240
about the situation where I was getting ready
00:08:01.240 --> 00:08:03.300
for this interview and I got a paper cut? What's
00:08:03.300 --> 00:08:05.839
happening at the cellular level to repair the
00:08:05.839 --> 00:08:08.879
damage? Well, I guess you provide a perfect example
00:08:08.879 --> 00:08:14.220
of how dangerous research can be. first of all
00:08:14.220 --> 00:08:17.220
just to say that that it's e -i -f -4 -e but
00:08:17.220 --> 00:08:19.819
we but you otherwise you said it perfectly but
00:08:19.819 --> 00:08:22.920
we nickname it 4e because that makes it much
00:08:22.920 --> 00:08:26.139
easier to say okay so if i'm going to use 4e
00:08:26.139 --> 00:08:28.339
for the rest of the so that way i don't have
00:08:28.339 --> 00:08:33.039
to go through exactly perfect exactly so A lot
00:08:33.039 --> 00:08:36.159
happens when you have your paper cut. A lot happens
00:08:36.159 --> 00:08:39.139
on the organism level and the cell level in order
00:08:39.139 --> 00:08:41.580
to heal that paper cut. Your body sends immune
00:08:41.580 --> 00:08:44.200
cells to clean up debris from the cut to get
00:08:44.200 --> 00:08:46.899
rid of damaged cells and to ensure that there
00:08:46.899 --> 00:08:50.059
is no infection. Then other cell types have to
00:08:50.059 --> 00:08:53.279
come and lay down a scaffold in order to heal
00:08:53.279 --> 00:08:56.519
the wound so that now it becomes seamless and
00:08:56.519 --> 00:08:58.399
you don't see, hopefully, your paper cut anymore.
00:08:58.740 --> 00:09:01.820
So at the cellular level, As I said, many different
00:09:01.820 --> 00:09:05.059
types of cells have many different things to
00:09:05.059 --> 00:09:08.200
do in this sort of very basic scenario that you've
00:09:08.200 --> 00:09:11.179
brought up. And these cells receive signals that
00:09:11.179 --> 00:09:13.580
something went wrong and that they might have
00:09:13.580 --> 00:09:16.759
to move in and fix things up. So many of these
00:09:16.759 --> 00:09:20.299
signals turn on programs at the DNA level. But
00:09:20.299 --> 00:09:22.980
where 4E is cool is that it can disconnect the
00:09:22.980 --> 00:09:26.480
DNA signals to produce the actors in the cell
00:09:26.480 --> 00:09:29.519
called proteins with altered functions that can
00:09:29.519 --> 00:09:32.600
respond much more quickly to this sort of wound
00:09:32.600 --> 00:09:35.700
scenario, adapt to these stressful situations.
00:09:36.240 --> 00:09:40.779
And so that's kind of an overview of what's going
00:09:40.779 --> 00:09:46.080
on there. Describing that 4E is part of the process
00:09:46.080 --> 00:09:49.019
by... allowing the cell to quickly adapt and
00:09:49.019 --> 00:09:52.620
produce other proteins to help fix the problem
00:09:52.620 --> 00:09:56.639
of a paper cut? Yes, exactly. 4E plays many roles,
00:09:56.740 --> 00:10:00.440
but by being able to reprogram DNA signals in
00:10:00.440 --> 00:10:03.399
order to adapt to the stress, it allows these
00:10:03.399 --> 00:10:09.259
much faster responses. It works through something
00:10:09.259 --> 00:10:12.500
called RNA, which many of your listeners may
00:10:12.500 --> 00:10:14.779
be familiar with because we had the COVID mRNA
00:10:14.779 --> 00:10:19.679
vaccines. But the message from DNA is called
00:10:19.679 --> 00:10:23.500
messenger RNA. And that message is supposed to
00:10:23.500 --> 00:10:28.159
be instructions the DNA sends into the part of
00:10:28.159 --> 00:10:31.080
the cell known as the cytoplasm. where that message
00:10:31.080 --> 00:10:33.320
gets turned into these protein actors I was referring
00:10:33.320 --> 00:10:37.639
to. And what proteins like 4E can do is modulate
00:10:37.639 --> 00:10:40.179
those instructions. So they change the instructions
00:10:40.179 --> 00:10:42.980
to adapt to stress, or sometimes they can get
00:10:42.980 --> 00:10:44.919
hijacked by a cancer cell, and then they're doing
00:10:44.919 --> 00:10:48.460
things that they shouldn't be doing. Okay, so
00:10:48.460 --> 00:10:51.500
if I'm looking for how our understanding of this
00:10:51.500 --> 00:10:55.240
protein has changed over time, I suppose that
00:10:55.240 --> 00:10:58.830
we didn't always think of it this way. What did
00:10:58.830 --> 00:11:00.889
we think about it when it was discovered in the
00:11:00.889 --> 00:11:05.950
1970s? So in the 1970s, it was able to disconnect
00:11:05.950 --> 00:11:09.870
the signals from DNA to protein by allowing...
00:11:10.299 --> 00:11:13.360
more protein to be made out of every single strand
00:11:13.360 --> 00:11:16.000
of messenger RNA you have. And so it was allowing
00:11:16.000 --> 00:11:19.840
an amplification of the signal. And so back in
00:11:19.840 --> 00:11:22.399
the 70s was when this protein was actually discovered
00:11:22.399 --> 00:11:24.940
to bind a really important part of the messenger
00:11:24.940 --> 00:11:29.200
RNA known as the methyl 7 -guanosine cap, or
00:11:29.200 --> 00:11:31.179
we'll just call it the cap for the purpose of
00:11:31.179 --> 00:11:34.700
our conversation. And this modification allows
00:11:34.700 --> 00:11:40.240
4E to be able to interact with RNAs. And what
00:11:40.240 --> 00:11:43.500
we've found since the sort of foundational studies
00:11:43.500 --> 00:11:47.100
of the 70s is that FORE can also do things that
00:11:47.100 --> 00:11:50.179
not only amplify the message through both this
00:11:50.179 --> 00:11:53.139
increased translational efficiency or increased
00:11:53.139 --> 00:11:55.600
efficiency of getting more protein out of a single
00:11:55.600 --> 00:11:59.980
RNA, also by rewriting the message or editing
00:11:59.980 --> 00:12:03.100
the sort of the RNA code, as it were, allowing
00:12:03.100 --> 00:12:05.820
big chunks to be shuffled in or out of the RNA.
00:12:05.960 --> 00:12:08.769
And this can... cause proteins to be made from
00:12:08.769 --> 00:12:11.049
that RNA, they can actually even have opposite
00:12:11.049 --> 00:12:13.450
functions to what the original instructions were
00:12:13.450 --> 00:12:16.690
that was sent. So for instance, a protein that
00:12:16.690 --> 00:12:19.289
might tell a cell, you're really damaged, you
00:12:19.289 --> 00:12:21.450
need to die now for the good of the organism,
00:12:21.710 --> 00:12:25.710
in a process called apoptosis, this same protein
00:12:25.710 --> 00:12:28.490
can end up or the instructions can be modified
00:12:28.490 --> 00:12:32.250
so that protein actually rescues cells from apoptosis
00:12:32.250 --> 00:12:35.289
or cell death. And that can obviously, in the
00:12:35.289 --> 00:12:38.090
case of a cancer cell, allow the cancer cell
00:12:38.090 --> 00:12:40.590
to keep on going when it should have listened
00:12:40.590 --> 00:12:44.309
to the signals to die. You know what? I'm going
00:12:44.309 --> 00:12:47.029
to skip all over the place here. So is there
00:12:47.029 --> 00:12:50.009
any other protein besides 4E that does a similar
00:12:50.009 --> 00:12:55.169
job? Yeah, there are other proteins. So what's
00:12:55.169 --> 00:12:59.720
being... sort of known today as opposed to when
00:12:59.720 --> 00:13:02.659
those studies in foray started in the 70s, is
00:13:02.659 --> 00:13:06.200
that the foray can affect many of the different
00:13:06.200 --> 00:13:09.820
chemical changes that RNA have to undergo in
00:13:09.820 --> 00:13:13.299
the process of called RNA maturation, allowing
00:13:13.299 --> 00:13:17.820
different also... kinetics for the capacity of
00:13:17.820 --> 00:13:20.419
the RNAs to move from the nucleus to the cytoplasm
00:13:20.419 --> 00:13:23.259
to be available to the machines that make proteins
00:13:23.259 --> 00:13:26.639
out of the RNA, as well as this capacity to make
00:13:26.639 --> 00:13:31.320
more protein out of any RNA. So there's other
00:13:31.320 --> 00:13:34.440
proteins that can work at some of these steps,
00:13:34.659 --> 00:13:38.799
but 4E seems to be one of the few that actually
00:13:38.799 --> 00:13:41.919
can act at all of these steps. And that's...
00:13:42.169 --> 00:13:44.710
really based on the fact that FORE can bind this
00:13:44.710 --> 00:13:47.210
central cap modification I was talking about
00:13:47.210 --> 00:13:51.169
before. That's the little module that FORE recognizes.
00:13:51.529 --> 00:13:55.929
And then FORE sort of changes which other partner
00:13:55.929 --> 00:14:00.330
cofactors at each step of the processing and
00:14:00.330 --> 00:14:03.690
then protein synthesis production scenarios.
00:14:04.950 --> 00:14:08.590
So is that the thing that's changed the most
00:14:08.590 --> 00:14:11.090
from the 70s? It's like, okay, we found this
00:14:11.090 --> 00:14:14.019
protein. does some pretty cool stuff. And then
00:14:14.019 --> 00:14:17.200
kind of fast forward into late 80s, 90s today,
00:14:17.299 --> 00:14:20.500
we're starting to understand just how integrated
00:14:20.500 --> 00:14:23.620
this is within the whole machinery from start
00:14:23.620 --> 00:14:27.460
to finish. Exactly. And what's very special about
00:14:27.460 --> 00:14:31.940
4E is that it also doesn't affect these chemical
00:14:31.940 --> 00:14:35.759
modifications to the RNAs or their export or
00:14:35.759 --> 00:14:38.559
their production into protein. It doesn't treat
00:14:38.559 --> 00:14:41.639
all RNAs equally. It has the specificity and
00:14:41.639 --> 00:14:44.259
a lot of the RNAs that it's specifically changing
00:14:44.259 --> 00:14:48.139
are RNAs that are involved in cell division,
00:14:48.440 --> 00:14:51.360
so creating more cells in a process we call proliferation.
00:14:51.740 --> 00:14:54.960
In cell movement in particular is a big one.
00:14:55.100 --> 00:14:58.240
So as we know, for instance, those cells that
00:14:58.240 --> 00:15:00.799
we talked about during your paper cut, we had
00:15:00.799 --> 00:15:03.789
to have cells be able to walk into the... into
00:15:03.789 --> 00:15:06.090
the paper cut and help start to clear out the
00:15:06.090 --> 00:15:08.570
debris. So cell movement is a normal function,
00:15:08.710 --> 00:15:11.309
which ends up being hijacked by cancer cells
00:15:11.309 --> 00:15:13.370
in the form of what we know, you know, disease
00:15:13.370 --> 00:15:16.409
spread and metastases. And also this capacity
00:15:16.409 --> 00:15:20.429
of 4E to be able to affect RNAs involved in making
00:15:20.429 --> 00:15:24.110
the choice of cells being able to survive a stress
00:15:24.110 --> 00:15:27.210
or cells listening to what they should listen
00:15:27.210 --> 00:15:32.750
to and die. So those... The specificity is something
00:15:32.750 --> 00:15:36.049
that's come through the years. But the biggest
00:15:36.049 --> 00:15:38.529
thing, I think, is the fact that it can affect
00:15:38.529 --> 00:15:42.629
so many different steps of this sort of protein
00:15:42.629 --> 00:15:46.350
production pathway. All right, now the pivot.
00:15:46.629 --> 00:15:49.909
I know it's a little bit of a cliche. What was
00:15:49.909 --> 00:15:53.549
the eureka moment or data or stack of moments,
00:15:53.629 --> 00:15:55.700
which is usually... more often the case, that
00:15:55.700 --> 00:15:59.100
kind of forced that rethink of 4E and put it
00:15:59.100 --> 00:16:00.679
on a path to today's understanding with respect
00:16:00.679 --> 00:16:05.620
to cancer? So I think for many, many years, it
00:16:05.620 --> 00:16:08.460
was considered to be very important in this role
00:16:08.460 --> 00:16:10.419
in protein synthesis, and that was considered
00:16:10.419 --> 00:16:12.960
its only role. So as we said, understanding these
00:16:12.960 --> 00:16:18.120
different roles really required the first observation.
00:16:19.360 --> 00:16:21.620
to be that foray was in the nuclear compartment
00:16:21.620 --> 00:16:24.679
of cells because the protein production part
00:16:24.679 --> 00:16:27.679
of cells is all in the cytoplasm. And so foray
00:16:27.679 --> 00:16:30.139
was considered to be only there and thus could
00:16:30.139 --> 00:16:32.980
only do things related to that compartment. In
00:16:32.980 --> 00:16:36.620
the 90s, some work by other groups had shown
00:16:36.620 --> 00:16:40.289
that that 4E could actually be in the cell nucleus
00:16:40.289 --> 00:16:44.710
of mammalian cells, so human cells, and also
00:16:44.710 --> 00:16:47.490
in yeast cells. And later studies even showed
00:16:47.490 --> 00:16:50.529
it in plant cells. So it seems that 4E being
00:16:50.529 --> 00:16:53.450
in a nucleus is actually quite ancient when we
00:16:53.450 --> 00:16:55.990
think about, you know, when was the last time
00:16:55.990 --> 00:17:00.269
animal plants and yeast were all sort of similar
00:17:00.269 --> 00:17:02.190
or, you know, derived from a similar organism.
00:17:02.710 --> 00:17:06.940
So the eureka moment for us. was I was working
00:17:06.940 --> 00:17:11.099
on actually a project related to viruses, completely
00:17:11.099 --> 00:17:13.759
unrelated to EIF -4E. In fact, I hardly even
00:17:13.759 --> 00:17:16.119
knew what EIF -4E was. And I just started my
00:17:16.119 --> 00:17:20.500
own lab. And we were using EIF -4E as a control
00:17:20.500 --> 00:17:22.980
because it was easy to buy antibodies for it,
00:17:23.000 --> 00:17:28.880
to be honest. And it turned out that in the control
00:17:28.880 --> 00:17:31.380
experiments, when I looked down the microscope,
00:17:31.500 --> 00:17:35.180
I saw 4E all over the nucleus. And I was like,
00:17:35.549 --> 00:17:38.069
What's that? And I started to look and there
00:17:38.069 --> 00:17:40.750
was only like two or three papers showing that
00:17:40.750 --> 00:17:42.569
that Fourier was in the nucleus. And it was sort
00:17:42.569 --> 00:17:44.890
of like, huh, we don't know. But it was there.
00:17:45.210 --> 00:17:49.190
And so we started to to dissect, you know, what
00:17:49.190 --> 00:17:52.210
could it possibly be doing there? So so really,
00:17:52.329 --> 00:17:55.109
it was completely serendipitous, as is a lot
00:17:55.109 --> 00:17:58.849
of research. And I guess as as we are both researchers,
00:17:58.990 --> 00:18:01.450
I think we understand that we write these very.
00:18:01.950 --> 00:18:04.730
tightly knit grants. But it's important to have
00:18:04.730 --> 00:18:07.569
the latitude to be able to to take one of those
00:18:07.569 --> 00:18:10.609
eureka moments and be able to build on it. Yeah,
00:18:10.730 --> 00:18:12.609
you never know where the research is going to
00:18:12.609 --> 00:18:14.730
go. And neither do the funding agencies that
00:18:14.730 --> 00:18:16.869
fund it. That's why you fund general science.
00:18:17.109 --> 00:18:19.130
And yeah, it's a little bit of a hope for the
00:18:19.130 --> 00:18:21.069
best. But at the same time, what you get out
00:18:21.069 --> 00:18:24.990
of it in the long run is just pretty amazing.
00:18:25.029 --> 00:18:27.049
Like the understanding the way it goes towards
00:18:27.049 --> 00:18:34.019
new drugs or new technologies or Etc. Okay, so
00:18:34.019 --> 00:18:37.299
one of the things that I found when looking this
00:18:37.299 --> 00:18:40.740
up and trying my best to understand it is an
00:18:40.740 --> 00:18:46.859
analogy to E4E being like a micromanager of the
00:18:46.859 --> 00:18:49.740
entire process. Is this kind of a fair representation?
00:18:50.539 --> 00:18:53.640
I thought it was a really cute analogy that you
00:18:53.640 --> 00:18:57.599
made. And for the RNAs that it affects, I think
00:18:57.599 --> 00:19:01.019
it's pretty true. because it's affecting so many
00:19:01.019 --> 00:19:05.319
steps where people, yeah, I like the analogy.
00:19:06.920 --> 00:19:11.279
Okay, so perhaps we'll go to an old saying to
00:19:11.279 --> 00:19:14.000
kind of look at this a little bit more. Too many
00:19:14.000 --> 00:19:16.259
cooks spoil the broth, or perhaps too few and
00:19:16.259 --> 00:19:17.940
we go hungry. So let's start with the later case.
00:19:18.019 --> 00:19:21.099
What happens if there's not enough 4E and the
00:19:21.099 --> 00:19:24.319
kitchen is empty? Is that even possible? So there
00:19:24.319 --> 00:19:29.690
are... There are examples, especially in neurology,
00:19:29.690 --> 00:19:34.589
where the loss of 4E can be associated with reduced
00:19:34.589 --> 00:19:40.069
activity of the neurons. I'm not an expert on
00:19:40.069 --> 00:19:42.950
neurology or neuroscience, but they impact the
00:19:42.950 --> 00:19:45.609
capacity of the neurons to send their chemical
00:19:45.609 --> 00:19:49.970
signals. by reducing the amount of the right
00:19:49.970 --> 00:19:53.849
proteins that are being made, so the right cofactors
00:19:53.849 --> 00:19:58.210
that need to send these signals. So yes, although
00:19:58.210 --> 00:20:00.069
I'm much more familiar with the cancer case,
00:20:00.230 --> 00:20:04.170
it has been observed. And also in neurology,
00:20:04.170 --> 00:20:08.910
there are cases where EIF -4E can be overactive.
00:20:09.559 --> 00:20:12.440
as is the case for diseases like Alzheimer's.
00:20:12.539 --> 00:20:16.339
But again, for that particular example, 4E can
00:20:16.339 --> 00:20:18.400
contribute, but there's also a whole plethora
00:20:18.400 --> 00:20:21.480
of other proteins that are really important to
00:20:21.480 --> 00:20:24.960
RNA biology as well and can also disconnect the
00:20:24.960 --> 00:20:27.720
sort of DNA instructions from the ultimate signal.
00:20:28.019 --> 00:20:32.579
So it's complicated, but definitely having too
00:20:32.579 --> 00:20:36.559
little is not good. There is very much a Goldilocks
00:20:36.559 --> 00:20:40.890
zone for 4E levels. And in fact, as an example
00:20:40.890 --> 00:20:43.470
of that in the lab, oftentimes to investigate
00:20:43.470 --> 00:20:49.349
the importance of a given factor to, say, survival
00:20:49.349 --> 00:20:54.309
of an organism is to make out mouse knockouts.
00:20:54.349 --> 00:20:58.250
And it was impossible to make a mouse knockout
00:20:58.250 --> 00:21:03.269
of 4E. So you mean remove the gene that would
00:21:03.269 --> 00:21:06.549
create 4E and then therefore the mouse was...
00:21:07.430 --> 00:21:10.250
In other words, it would just automatically die
00:21:10.250 --> 00:21:17.349
in fetus? Yes, as an early embryo. Like a couple
00:21:17.349 --> 00:21:20.869
of divisions and then it just, it's gone. So
00:21:20.869 --> 00:21:24.190
you can reduce it by about half and the mice
00:21:24.190 --> 00:21:26.650
are completely fine and don't seem to have any
00:21:26.650 --> 00:21:30.430
problems at all. But completely removing it was
00:21:30.430 --> 00:21:35.269
a no -go. Okay, so what... Your lab primarily
00:21:35.269 --> 00:21:38.890
deals with leukemia and cancer. So what happens
00:21:38.890 --> 00:21:42.829
to the micromanagers in these cases? What happens
00:21:42.829 --> 00:21:46.470
to our machinery? So it turns out that 4E can
00:21:46.470 --> 00:21:49.160
be elevated in a lot of cancers. be familiar
00:21:49.160 --> 00:21:51.819
with like prostate, breast, lung cancer. Not
00:21:51.819 --> 00:21:54.480
necessarily in every case, usually in a subset
00:21:54.480 --> 00:21:58.059
of patients will have this elevation. So it's
00:21:58.059 --> 00:22:00.039
not homogeneous, if you see what I mean, for
00:22:00.039 --> 00:22:03.059
each cancer. And that's also true of acute myeloid
00:22:03.059 --> 00:22:05.440
leukemia or AML, which is leukemia I work on.
00:22:05.500 --> 00:22:08.180
So there's a subset of patients that have elevated
00:22:08.180 --> 00:22:13.180
4E. And that elevation of 4E predicts poor outcomes.
00:22:14.000 --> 00:22:18.109
So obviously having... Too much 4E in the cancer
00:22:18.109 --> 00:22:22.769
cells is not serving the organism very well.
00:22:23.029 --> 00:22:26.690
So my lab, first of all, wanted to understand
00:22:26.690 --> 00:22:30.609
how is 4E causing, elevation of 4E causing disease?
00:22:30.930 --> 00:22:34.309
And secondly, like, could we target it? So to
00:22:34.309 --> 00:22:37.269
answer the first question is kind of I alluded
00:22:37.269 --> 00:22:40.509
to before, is that 4E really, through all of
00:22:40.509 --> 00:22:44.940
these different... modifications to the RNA and
00:22:44.940 --> 00:22:48.559
to the impacts on protein synthesis can make
00:22:48.559 --> 00:22:52.240
factors that allow the cells to ignore signaling
00:22:52.240 --> 00:22:56.000
that says that you should die. They allow the
00:22:56.000 --> 00:22:58.880
cells to move through the body more readily,
00:22:59.119 --> 00:23:02.000
escaping from the bone marrow and being found
00:23:02.000 --> 00:23:05.420
even in the central nervous system or the skin.
00:23:05.619 --> 00:23:11.880
So very large capacity to be able to move. I
00:23:11.880 --> 00:23:14.380
think understanding the molecular basis of those
00:23:14.380 --> 00:23:17.720
was really important for setting up a sort of
00:23:17.720 --> 00:23:24.559
plan in order to try to target in patients. And
00:23:24.559 --> 00:23:27.220
in the patient side, we developed a strategy
00:23:27.220 --> 00:23:32.279
that was, I guess, 15, 20 years ago was the first
00:23:32.279 --> 00:23:37.779
clinical trial was 2009. And we found a small
00:23:37.779 --> 00:23:40.200
old antiviral drug, which is actually kind of
00:23:40.200 --> 00:23:43.240
based. on the virus I originally was looking
00:23:43.240 --> 00:23:46.460
at when I first found that 4E was in the nucleus
00:23:46.460 --> 00:23:49.259
and could... You came full circle. Yeah, so we
00:23:49.259 --> 00:23:52.099
came full circle. So it was the only treatment
00:23:52.099 --> 00:23:55.339
for that particular virus called ribavirin. And
00:23:55.339 --> 00:23:58.640
this old antiviral drug has been known for...
00:23:59.180 --> 00:24:02.039
since the 70s to be completely safe. So we had
00:24:02.039 --> 00:24:04.619
this really nice position. It's also a generic
00:24:04.619 --> 00:24:07.160
drug, which can lead us into a completely different
00:24:07.160 --> 00:24:10.960
conversation about how drug discovery and clinical
00:24:10.960 --> 00:24:16.359
trial funding works in the independent investigator
00:24:16.359 --> 00:24:19.740
versus big pharma worlds. But anyways, what we
00:24:19.740 --> 00:24:22.380
found was really striking. We took... AML patients
00:24:22.380 --> 00:24:25.740
that had previously failed their chemotherapy
00:24:25.740 --> 00:24:28.420
or they never responded to the original chemotherapy.
00:24:28.680 --> 00:24:30.700
And that's normally the patients that you get
00:24:30.700 --> 00:24:33.779
in clinical trials. So they can already start
00:24:33.779 --> 00:24:39.319
to have signs of drug resistance. So these trials
00:24:39.319 --> 00:24:42.019
are more challenging, I think, and make it harder
00:24:42.019 --> 00:24:46.740
to see signals. And so we were really excited
00:24:46.740 --> 00:24:50.380
that we had patients that had complete and partial
00:24:50.380 --> 00:24:53.700
remissions just taking ribavirin as a monotherapy.
00:24:54.220 --> 00:24:56.420
And you can take ribavirin as a pill so they
00:24:56.420 --> 00:24:58.880
could take it at home, which is like the ideal
00:24:58.880 --> 00:25:02.359
scenario, right? So we had about 30 % to 40 %
00:25:02.359 --> 00:25:05.299
of patients had this sort of really nice, strong,
00:25:05.359 --> 00:25:08.319
objective clinical responses. But eventually,
00:25:08.420 --> 00:25:10.660
all the patients would become drug resistant,
00:25:10.859 --> 00:25:14.660
which is common, particularly in monotherapies,
00:25:14.700 --> 00:25:19.470
but common in drug chemistry. generally. And
00:25:19.470 --> 00:25:22.230
most cancers are not treated with a single agent,
00:25:22.349 --> 00:25:26.269
right? So we wanted to find combinations that
00:25:26.269 --> 00:25:30.769
allowed us to increase the percentage of patients
00:25:30.769 --> 00:25:33.289
that had responses and also the length of the
00:25:33.289 --> 00:25:36.230
drug responses. So for instance, in the first
00:25:36.230 --> 00:25:39.450
trial, the standard of care of the time would
00:25:39.450 --> 00:25:44.099
give on average seven months survival. And we
00:25:44.099 --> 00:25:48.720
had patients out to two years. So that was definitely
00:25:48.720 --> 00:25:51.619
very promising, although these are all early
00:25:51.619 --> 00:25:54.180
stage clinical trials, right? So small numbers.
00:25:54.740 --> 00:25:57.740
But we tried some combinations and we were always
00:25:57.740 --> 00:26:02.000
sort of hitting the same kind of mark of we were
00:26:02.000 --> 00:26:03.900
getting responses, which was great, but the patients
00:26:03.900 --> 00:26:06.740
would become... drug resistance. So we actually
00:26:06.740 --> 00:26:09.059
decided to try to figure out what the resistance
00:26:09.059 --> 00:26:11.759
was, and then we could use that as a combination
00:26:11.759 --> 00:26:16.220
therapy. And we found that what was happening
00:26:16.220 --> 00:26:20.319
to the ribavirin drug in the leukemia cells was
00:26:20.319 --> 00:26:24.660
that there was a... a small sugar molecule called
00:26:24.660 --> 00:26:27.039
glucuronic acid that was covalently added to
00:26:27.039 --> 00:26:30.039
the ribavirin. And that made it no longer bind
00:26:30.039 --> 00:26:33.660
4E and it made the cells completely resistant
00:26:33.660 --> 00:26:36.579
to not only 4E, not only to ribavirin, but to
00:26:36.579 --> 00:26:39.880
many common chemotherapies. So we found that
00:26:39.880 --> 00:26:43.619
this drug resistance mechanism was really relevant
00:26:43.619 --> 00:26:47.519
to a broad range of drugs. And what was really
00:26:47.519 --> 00:26:50.900
striking was that that... had been previously
00:26:50.900 --> 00:26:53.259
considered that this form of adding this sugar
00:26:53.259 --> 00:26:56.140
onto the drug called glucuronidation could only
00:26:56.140 --> 00:26:58.640
happen in the liver. And what we were seeing
00:26:58.640 --> 00:27:01.200
is that the cancer cells had evolved the enzymes,
00:27:01.240 --> 00:27:04.180
or turned back on the enzymes that were usually
00:27:04.180 --> 00:27:07.660
liver -specific in order to now be able to evade
00:27:07.660 --> 00:27:13.180
this therapy. So if you're a Star Trek fan, they
00:27:13.180 --> 00:27:16.880
remind me of the Borg. So... Resistance is futile.
00:27:17.230 --> 00:27:19.289
Yes. I even wrote a review called Resistance
00:27:19.289 --> 00:27:23.589
is Futile. But yes. And they say scientists don't
00:27:23.589 --> 00:27:27.710
have a sense of humor. Thank you. Yes. So we
00:27:27.710 --> 00:27:31.250
went on to do a clinical trial in patients where
00:27:31.250 --> 00:27:33.930
we had figured out how to target the drug resistance,
00:27:34.269 --> 00:27:37.829
this form of drug resistance, in patients that
00:27:37.829 --> 00:27:40.650
were already had failed like three to four other
00:27:40.650 --> 00:27:43.269
types of therapy. So very... drug -resistant
00:27:43.269 --> 00:27:46.109
patients. And we could see some clinical responses.
00:27:46.269 --> 00:27:49.470
We even had a remission in our small group. But
00:27:49.470 --> 00:27:52.109
then those patients became resistant to the drug
00:27:52.109 --> 00:27:54.289
that we had used to overcome the resistance.
00:27:54.869 --> 00:27:59.269
So I know it's both sad and ironic because I
00:27:59.269 --> 00:28:02.549
think it's a big challenge in clinical trial
00:28:02.549 --> 00:28:05.349
development for these drugs because especially
00:28:05.349 --> 00:28:09.509
when you're treating heavily refractory patients.
00:28:10.519 --> 00:28:14.000
Their cancer cells have been trained to evade
00:28:14.000 --> 00:28:16.380
a wide array of drugs. Those are the survivor
00:28:16.380 --> 00:28:21.720
ones. So they're that much more resilient, unfortunately.
00:28:22.299 --> 00:28:26.359
But I am excited to say that we hope in the winter
00:28:26.359 --> 00:28:29.359
of 2027 at Northwestern, we're going to be starting
00:28:29.359 --> 00:28:32.220
a new trial, including ribavirin with the standard
00:28:32.220 --> 00:28:35.279
of care in upfront patients, so patients who
00:28:35.279 --> 00:28:40.019
haven't received any treatment yet. And I also
00:28:40.019 --> 00:28:43.240
should say one of the nice things that we did
00:28:43.240 --> 00:28:46.779
that a lot of clinical trials do not do, especially
00:28:46.779 --> 00:28:50.359
industry trials, is that we developed assays
00:28:50.359 --> 00:28:52.599
to check that the ribavirin was really targeting
00:28:52.599 --> 00:28:54.819
the 4E in the patients and that we could really
00:28:54.819 --> 00:28:58.299
correlate the 4E targeting with the clinical
00:28:58.299 --> 00:29:01.720
responses, which was very satisfying because
00:29:01.720 --> 00:29:04.980
we could see the resistance patients, the ribavirin
00:29:04.980 --> 00:29:07.519
didn't do anything to their 4E, the responding
00:29:07.519 --> 00:29:12.160
patients. we had nice impacts on 4E activity.
00:29:12.720 --> 00:29:16.339
Let's go with, so you said that some cancers
00:29:16.339 --> 00:29:21.619
show an increase of 4E and many do not, but would
00:29:21.619 --> 00:29:26.559
trying to control 4E still potentially help those
00:29:26.559 --> 00:29:30.619
without an increase in 4E? Yeah, I think potentially
00:29:30.619 --> 00:29:34.460
it would. The clinical trials that we ran are...
00:29:34.920 --> 00:29:36.940
They were funded by the Leukemia and Lymphoma
00:29:36.940 --> 00:29:39.440
Society US and Leukemia and Lymphoma Society
00:29:39.440 --> 00:29:42.799
Canada. So a big shout out to them. And so the
00:29:42.799 --> 00:29:46.799
budgets in those trials are, you have to have
00:29:46.799 --> 00:29:48.920
a randomized group of people that have high and
00:29:48.920 --> 00:29:51.839
low 4E and be able to make some statistics. And
00:29:51.839 --> 00:29:55.960
in that sort of realm with these early stage
00:29:55.960 --> 00:29:58.710
clinical trials, we just don't have the... capacity
00:29:58.710 --> 00:30:00.710
to investigate that. But I think theoretically
00:30:00.710 --> 00:30:03.069
it could be really interesting. Is there any
00:30:03.069 --> 00:30:07.630
risk of giving this drug early or to someone
00:30:07.630 --> 00:30:11.210
who doesn't have cancer and then later the cells
00:30:11.210 --> 00:30:14.029
are resistant to it? Like it holds that memory?
00:30:14.450 --> 00:30:18.990
I think that we discussed that possibility and
00:30:18.990 --> 00:30:23.150
I would... I would say that it is possible. I
00:30:23.150 --> 00:30:24.890
don't think that I would give someone ribavirin
00:30:24.890 --> 00:30:27.109
as a preventative anti -cancer to take the rest
00:30:27.109 --> 00:30:30.150
of their life because of this. Also, what happened
00:30:30.150 --> 00:30:32.130
with this drug resistance is it caused cross
00:30:32.130 --> 00:30:34.049
-resistance, so it became resistant to other
00:30:34.049 --> 00:30:37.509
cancer drugs, these cells. So I think you'd really
00:30:37.509 --> 00:30:42.700
want to go in. when it's happening. Now, ribavirin
00:30:42.700 --> 00:30:45.980
is an old generic drug. There's no intellectual
00:30:45.980 --> 00:30:48.799
property on it or anything, right? So I'm sure
00:30:48.799 --> 00:30:51.000
that there will be drugs, and there are like
00:30:51.000 --> 00:30:55.339
trials going on using different strategies to
00:30:55.339 --> 00:30:59.099
also target 4E. And so some of these new means
00:30:59.099 --> 00:31:02.240
to target it may be better. Although I do have
00:31:02.240 --> 00:31:06.740
to say that the early trial data, for instance,
00:31:08.029 --> 00:31:11.470
4E can be modified by phosphorylation, which
00:31:11.470 --> 00:31:14.450
is an important aspect of its cancer -causing
00:31:14.450 --> 00:31:17.450
activities. But in heavily pretreated patients,
00:31:17.569 --> 00:31:20.490
there was no statistical clinical benefit, whereas
00:31:20.490 --> 00:31:24.630
ribavirin was giving remission. And there's also
00:31:24.630 --> 00:31:27.410
genetic ways to target 4E that have been tried
00:31:27.410 --> 00:31:30.950
in two different clinical trials using something
00:31:30.950 --> 00:31:34.349
called antisense oligonucleotides. That's a mouthful.
00:31:34.779 --> 00:31:38.019
Yeah, yeah. So it's a way to genetically reduce
00:31:38.019 --> 00:31:41.640
4E. And it works really well in mice and gives
00:31:41.640 --> 00:31:45.339
really nice response in mice. But in people,
00:31:45.460 --> 00:31:48.259
it doesn't cause any difference in their 4E protein
00:31:48.259 --> 00:31:51.500
levels. So thus, you're not surprised that it
00:31:51.500 --> 00:31:54.960
didn't cause any objective clinical responses,
00:31:55.019 --> 00:31:59.519
really. But there's a lot of interest now that
00:31:59.519 --> 00:32:03.230
people realize from our work. in people and from
00:32:03.230 --> 00:32:06.210
previous vast amount of work by many groups in
00:32:06.210 --> 00:32:10.369
mice, that 4E is worth targeting, that these
00:32:10.369 --> 00:32:13.569
companies may come up with new ways so that we
00:32:13.569 --> 00:32:15.269
don't have to worry about this drug resistance
00:32:15.269 --> 00:32:18.549
phenomena. I personally think, though, what we
00:32:18.549 --> 00:32:21.809
really need to do is probably to find the right
00:32:21.809 --> 00:32:27.210
combination of drugs to target 4E and some compensatory
00:32:27.210 --> 00:32:30.289
mechanism that may be turned on once you hit
00:32:30.289 --> 00:32:33.650
4E. And knowing that mechanism, those factors,
00:32:34.009 --> 00:32:36.369
then you could start to design another round
00:32:36.369 --> 00:32:41.809
of smart therapy, I hope. Sure. And I think something
00:32:41.809 --> 00:32:45.490
you said there about the potential for drug resistance
00:32:45.490 --> 00:32:49.309
is, sure, based on what you described, the drug
00:32:49.309 --> 00:32:51.470
works great, seems to have a really good safety
00:32:51.470 --> 00:32:54.529
profile. But at the same time, any intervention
00:32:54.529 --> 00:32:57.980
does have. changes and you have to make sure
00:32:57.980 --> 00:32:59.980
that whatever intervention whatever risks you're
00:32:59.980 --> 00:33:02.460
putting in is much smaller than what the result
00:33:02.460 --> 00:33:05.160
you're trying to get right absolutely patient
00:33:05.160 --> 00:33:09.220
safety first absolutely um so we've talked about
00:33:09.220 --> 00:33:13.500
all of this so far and you've kind of mentioned
00:33:13.500 --> 00:33:16.839
that it's cell division cell movement cell repair
00:33:16.839 --> 00:33:21.619
those are the things that 4e target right well
00:33:21.619 --> 00:33:24.250
so It targets proliferation a little bit. I did
00:33:24.250 --> 00:33:26.829
mention it, but really cell movement and rescue
00:33:26.829 --> 00:33:29.150
from cell death, I think, are the two major things,
00:33:29.210 --> 00:33:32.450
at least in leukemia cells, and differentiation.
00:33:32.829 --> 00:33:35.569
FORE can also block the capacity of a blood cell
00:33:35.569 --> 00:33:38.769
to differentiate into a mature form, which makes
00:33:38.769 --> 00:33:42.009
sense because leukemia is all about having too
00:33:42.009 --> 00:33:45.569
many immature blood cells. So how does that...
00:33:45.799 --> 00:33:48.880
come together with the new cancer vaccines that
00:33:48.880 --> 00:33:50.619
we're seeing that's trying to teach the immune
00:33:50.619 --> 00:33:55.859
system to kill the cells instead of 4E to essentially
00:33:55.859 --> 00:33:59.940
tell the cell to die? Is there a difference of
00:33:59.940 --> 00:34:02.559
a way those two mechanisms, like obviously the
00:34:02.559 --> 00:34:04.279
two mechanisms are different, but can be they
00:34:04.279 --> 00:34:08.500
targeted the same way or differently? Yeah, I
00:34:08.500 --> 00:34:11.780
mean, I would require some more thought to answer
00:34:11.780 --> 00:34:14.480
that deeply, but I think it's important to remember
00:34:14.480 --> 00:34:18.190
here that like, We're talking about the cancer
00:34:18.190 --> 00:34:20.409
cell and what the cancer cell is doing, and we
00:34:20.409 --> 00:34:22.349
haven't really talked too much about its immune
00:34:22.349 --> 00:34:26.769
interactions. In one of the clinical studies
00:34:26.769 --> 00:34:30.030
I discussed, one of the PD -L inhibitors was
00:34:30.030 --> 00:34:34.329
used in combination with this drug that inhibits
00:34:34.329 --> 00:34:37.530
Fourier modification by phosphorylation. And
00:34:37.530 --> 00:34:41.489
unfortunately, the... drug company study didn't
00:34:41.489 --> 00:34:44.329
really do any molecular analysis. So I can't
00:34:44.329 --> 00:34:47.190
really speak to whether the targets were hit,
00:34:47.190 --> 00:34:49.949
if things worked as expected or not, which I
00:34:49.949 --> 00:34:52.849
think is so central to our understanding of building
00:34:52.849 --> 00:34:55.909
from clinical science to back to the lab and
00:34:55.909 --> 00:34:58.869
then back to the bench, right? Bench to bedside.
00:34:59.130 --> 00:35:01.230
So I do think it's important. And one of the
00:35:01.230 --> 00:35:03.329
things that's sort of interesting is some recent
00:35:03.329 --> 00:35:07.539
studies have shown that 4A dysregulation influences
00:35:07.539 --> 00:35:10.360
not only the cancer cell, but can influence what
00:35:10.360 --> 00:35:13.000
we call the tumor microenvironment. So those
00:35:13.000 --> 00:35:15.000
are the cells around the cancer cell, which can
00:35:15.000 --> 00:35:17.679
include immune cells that you alluded to. And
00:35:17.679 --> 00:35:21.719
that some of the changes that we've noted for
00:35:21.719 --> 00:35:25.039
you can do in the cancer cell, they can also
00:35:25.039 --> 00:35:28.260
happen in this tumor microenvironment, and they
00:35:28.260 --> 00:35:31.829
can make the tumor microenvironment more permissive
00:35:31.829 --> 00:35:34.210
of having a tumor there. Because normally the
00:35:34.210 --> 00:35:36.909
job of the tumor microenvironment is to, as you
00:35:36.909 --> 00:35:39.510
say, send out the immune cells and just clear
00:35:39.510 --> 00:35:45.670
this bad actor out. But in this case, it allows
00:35:45.670 --> 00:35:48.750
this permissive environment that actually can
00:35:48.750 --> 00:35:51.489
even not only just allow it to grow, but actually
00:35:51.489 --> 00:35:56.690
help them to grow. It's really, I think, the
00:35:56.690 --> 00:35:59.969
next big area for probably for 4E is to understand
00:35:59.969 --> 00:36:03.110
these sort of interactions. So it's part of the
00:36:03.110 --> 00:36:06.269
bigger picture of just what allows cancer to
00:36:06.269 --> 00:36:09.309
evolve and change and stay around, even though
00:36:09.309 --> 00:36:13.789
it really shouldn't be there. Yes. Yes. All right.
00:36:13.829 --> 00:36:15.610
So we've already talked a little bit about some
00:36:15.610 --> 00:36:18.489
big picture stuff with the fact that 4E is involved
00:36:18.489 --> 00:36:22.440
with a lot of other... potential diseases through
00:36:22.440 --> 00:36:25.880
neurology, dementia, Alzheimer's. But where is
00:36:25.880 --> 00:36:27.960
this all going? Like, get out your crystal ball.
00:36:28.139 --> 00:36:31.019
And I know it's always a bit of a lark to try
00:36:31.019 --> 00:36:33.920
to forward and future cast. But are we slowly
00:36:33.920 --> 00:36:36.559
learning how to control our own machinery with
00:36:36.559 --> 00:36:40.420
4E as an important mechanism? I hope so. I think
00:36:40.420 --> 00:36:43.159
that we've shown it can be controlled, that we
00:36:43.159 --> 00:36:47.179
can benefit from it. We've done a lot of... biochemical
00:36:47.179 --> 00:36:50.340
and molecular biology assays to really understand
00:36:50.340 --> 00:36:55.559
at the molecular level how these things are happening.
00:36:55.800 --> 00:36:59.579
And obviously, there's much more mechanism to
00:36:59.579 --> 00:37:02.760
dissect and understand. And understanding those
00:37:02.760 --> 00:37:07.880
mechanisms help us develop or see new crucial
00:37:07.880 --> 00:37:11.280
intervention points that could be potentially
00:37:11.280 --> 00:37:16.280
used to make foray inhibition more effective
00:37:16.280 --> 00:37:19.039
or maybe inhibiting something else in the same
00:37:19.039 --> 00:37:21.639
pathway might work better because we don't have
00:37:21.639 --> 00:37:25.599
compensation. So I think back to the basic science
00:37:25.599 --> 00:37:29.000
is always going to instruct how we move forward.
00:37:29.179 --> 00:37:31.960
And I think that now that we have this clearer
00:37:31.960 --> 00:37:36.880
view of 4E and all of its roles, and not just
00:37:36.880 --> 00:37:39.579
one of its roles, will help us, you know, all
00:37:39.579 --> 00:37:44.280
of its roles being the nuclear RNA. changes to
00:37:44.280 --> 00:37:47.480
the RNA instructions through the export and then
00:37:47.480 --> 00:37:49.260
into the protein synthesis, by understanding
00:37:49.260 --> 00:37:53.280
this as not just a single step, that our intervention
00:37:53.280 --> 00:37:56.460
needs to be considered more globally in terms
00:37:56.460 --> 00:37:58.960
of the impact. And by understanding the molecular
00:37:58.960 --> 00:38:01.139
basis of these, I think that that can help us
00:38:01.139 --> 00:38:04.300
not only understand cool RNA biology, which I
00:38:04.300 --> 00:38:06.880
think is worthy of understanding of its own,
00:38:06.940 --> 00:38:10.039
just like a... poet likes writing poetry, it's
00:38:10.039 --> 00:38:13.519
worthy of it, but also from the practical aspect
00:38:13.519 --> 00:38:18.360
to be able to come up with better clinical interventions,
00:38:18.420 --> 00:38:21.760
both for neurodegeneration and for cancer. Now
00:38:21.760 --> 00:38:24.880
that is a perfect way to end the science portion
00:38:24.880 --> 00:38:28.139
of it, because it wraps it all up. It's one big
00:38:28.139 --> 00:38:32.980
picture. It's great. I love that. Now it's time
00:38:32.980 --> 00:38:36.679
for call -outs. I don't know, future work, colleagues.
00:38:37.769 --> 00:38:41.010
Anything you want. I really wanted there's so
00:38:41.010 --> 00:38:44.050
many people to thank for all the work I did.
00:38:44.110 --> 00:38:47.789
And I apologize to to people who wrote the papers.
00:38:47.829 --> 00:38:50.550
I didn't have time to talk or give references
00:38:50.550 --> 00:38:54.599
for. But the biggest shout out is. patients and
00:38:54.599 --> 00:38:57.420
their families that they were willing to take
00:38:57.420 --> 00:39:00.719
this risk. When you join a clinical trial with
00:39:00.719 --> 00:39:03.639
advanced cancer, you're first informed that this
00:39:03.639 --> 00:39:05.880
clinical trial is probably not going to help
00:39:05.880 --> 00:39:09.460
you. You're helping the future. And so I'm, first
00:39:09.460 --> 00:39:11.820
of all, glad we were able to help some, but those
00:39:11.820 --> 00:39:14.280
people did the trial anyways. And I think, and
00:39:14.280 --> 00:39:16.179
they went through and they got samples that we
00:39:16.179 --> 00:39:19.239
could study that allowed us to understand the
00:39:19.239 --> 00:39:21.199
drug resistance, allowed us to understand a lot
00:39:21.199 --> 00:39:25.420
of the what's going on in the person. And so
00:39:25.420 --> 00:39:28.460
that was awesome. I also have to have a huge
00:39:28.460 --> 00:39:32.059
shout out to Dr. Sarit Asselin at McGill, because
00:39:32.059 --> 00:39:34.860
she ran the, she's a medical monitor. She's a
00:39:34.860 --> 00:39:38.579
hematologist and chief of hematology now at the
00:39:38.579 --> 00:39:41.260
Lady, at the Jewish General Hospital. And so
00:39:41.260 --> 00:39:43.699
without her, this work couldn't be done. I also
00:39:43.699 --> 00:39:46.179
want to thank Morris and David Goodman at PharmaScience
00:39:46.179 --> 00:39:49.300
in Montreal, because they provided us free ribavirin,
00:39:49.360 --> 00:39:52.349
which, you know. was a big, big help and also
00:39:52.349 --> 00:39:55.369
some free other drugs that we used and gave us
00:39:55.369 --> 00:39:58.210
some analytical chemistry support, which allowed
00:39:58.210 --> 00:40:01.210
us to further dissect the drug resistance mechanism
00:40:01.210 --> 00:40:04.210
I referred to. A big shout out to all my lab
00:40:04.210 --> 00:40:07.710
team members, past and present, the funders like
00:40:07.710 --> 00:40:10.489
the NIH, the Leukemia and Lymphoma Society of
00:40:10.489 --> 00:40:14.190
Canada in the US and CIHR, and also to Shira
00:40:14.190 --> 00:40:17.170
Dinner and Jessica Altman, who are the clinical
00:40:17.170 --> 00:40:19.730
leads for the new trial that we're about to embark
00:40:19.730 --> 00:40:23.269
on. Okay. See, it really does take a whole team
00:40:23.269 --> 00:40:25.289
and a group of individuals to conduct science
00:40:25.289 --> 00:40:28.829
at the highest levels. It really does. No other
00:40:28.829 --> 00:40:32.309
ways around it. But now, we're at the infamous
00:40:32.309 --> 00:40:35.510
last question here on Whimsical Wavelengths,
00:40:35.510 --> 00:40:38.769
where my guest tells us all their favorite science
00:40:38.769 --> 00:40:44.010
joke. Okay. It's pretty corny. That doesn't matter.
00:40:44.369 --> 00:40:48.489
Come on. Just embrace it. Why can't you trust
00:40:48.489 --> 00:40:53.219
an atom? I don't know. They make up everything.
00:40:55.400 --> 00:41:00.599
Well, thank you so much for coming on Whimsical
00:41:00.599 --> 00:41:02.360
Wavelengths and sharing your science with us.
00:41:02.760 --> 00:41:05.380
Thanks, Jeff, so much for doing this podcast
00:41:05.380 --> 00:41:08.199
and making science popular. I have never been
00:41:08.199 --> 00:41:11.139
accused of being popular, and maybe I'll actually
00:41:11.139 --> 00:41:13.599
succeed in making science popular. But you've
00:41:13.599 --> 00:41:17.039
been with me this long, so... by all means, subscribe.
00:41:17.179 --> 00:41:19.739
Leave a review. You have no idea how important
00:41:19.739 --> 00:41:21.400
those are. It doesn't matter which app you use.
00:41:21.579 --> 00:41:27.500
Please leave a review. Yeah. And that's Season
00:41:27.500 --> 00:41:31.300
3, Episode 2 in the books. I'll see you again.
00:41:31.659 --> 00:41:54.119
Two weeks. Swaying to rhythms as the galaxies
00:41:54.119 --> 00:42:19.829
fly by. J.